Aligos Therapeutics Inc
ALGS
Company Profile
Business description
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Contact
One Corporate Drive
2nd Floor
South San FranciscoCA94080
USAT: +1 800 466-6059
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
stocks
3 cheap wide moat growth stocks
4 and 5 star companies that can protect and grow their earnings.
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,910.90 | 36.40 | 0.41% |
| CAC 40 | 8,186.93 | 0.00 | 0.00% |
| DAX 40 | 25,716.71 | 178.96 | 0.70% |
| Dow JONES (US) | 51,777.31 | 315.41 | 0.61% |
| FTSE 100 | 10,816.14 | 127.67 | 1.19% |
| HKSE | 24,604.29 | 109.49 | -0.44% |
| NASDAQ | 26,382.08 | 403.66 | 1.55% |
| Nikkei 225 | 64,136.25 | 213.25 | 0.33% |
| NZX 50 Index | 13,756.59 | 133.87 | 0.98% |
| S&P 500 | 7,630.78 | 78.97 | 1.05% |
| S&P/ASX 200 | 8,732.40 | 35.90 | 0.41% |
| SSE Composite Index | 3,875.60 | 16.00 | -0.41% |